106 related articles for article (PubMed ID: 7927883)
1. Establishment of a human small-cell lung-cancer subline resistant to okadaic acid.
Takeda Y; Nishio K; Kubota N; Miura K; Morikage T; Ohmori T; Kudoh S; Niitani H; Saijo N
Int J Cancer; 1994 Sep; 58(6):882-90. PubMed ID: 7927883
[TBL] [Abstract][Full Text] [Related]
2. Cross-resistance to antineoplastic agents in a human small-cell lung-cancer subline resistant to okadaic Acid.
Takeda Y; Kubota N; Nishio K; Funayama Y; Gemma A; Niitani H; Saijo N
Oncol Rep; 1995 Sep; 2(5):705-10. PubMed ID: 21597801
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the PP2A alpha gene mutation in okadaic acid-resistant variants of CHO-K1 cells.
Shima H; Tohda H; Aonuma S; Nakayasu M; DePaoli-Roach AA; Sugimura T; Nagao M
Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9267-71. PubMed ID: 7937753
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a taxol-resistant human small-cell lung cancer cell line.
Ohta S; Nishio K; Kubota N; Ohmori T; Funayama Y; Ohira T; Nakajima H; Adachi M; Saijo N
Jpn J Cancer Res; 1994 Mar; 85(3):290-7. PubMed ID: 7514586
[TBL] [Abstract][Full Text] [Related]
5. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.
Rhodes T; Twentyman PR
Br J Cancer; 1992 May; 65(5):684-90. PubMed ID: 1316774
[TBL] [Abstract][Full Text] [Related]
6. Increased phosphorylation of nuclear phosphoproteins in human lung-cancer cells resistant to cis-diamminedichloroplatinum (II).
Nishio K; Sugimoto Y; Kasahara K; Fujiwara Y; Nishiwaki S; Fujiki H; Ohata M; Saijo N
Int J Cancer; 1992 Feb; 50(3):438-42. PubMed ID: 1310490
[TBL] [Abstract][Full Text] [Related]
7. Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C-epsilon, exhibits multidrug resistance phenotype, and expresses drug pump P-glycoprotein.
Zheng B; Chambers TC; Raynor RL; Markham PN; Gebel HM; Vogler WR; Kuo JF
J Biol Chem; 1994 Apr; 269(16):12332-8. PubMed ID: 7512966
[TBL] [Abstract][Full Text] [Related]
8. The phosphatase inhibitor okadaic acid stimulates the TSH-induced G1-S phase transition in thyroid cells.
Lazzereschi D; Coppa A; Minicione G; Lavitrano M; Fragomele F; Colletta G
Exp Cell Res; 1997 Aug; 234(2):425-33. PubMed ID: 9260913
[TBL] [Abstract][Full Text] [Related]
9. Cellular models of drug- and radiation-resistant small cell lung cancer.
Davey RA; Locke VL; Henness S; Harvie RM; Davey MW
Anticancer Res; 2004; 24(2A):465-71. PubMed ID: 15152945
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells.
Messner DJ; Romeo C; Boynton A; Rossie S
J Cell Biochem; 2006 Sep; 99(1):241-55. PubMed ID: 16598789
[TBL] [Abstract][Full Text] [Related]
11. Dephosphorylation of cdc25-C by a type-2A protein phosphatase: specific regulation during the cell cycle in Xenopus egg extracts.
Clarke PR; Hoffmann I; Draetta G; Karsenti E
Mol Biol Cell; 1993 Apr; 4(4):397-411. PubMed ID: 8389619
[TBL] [Abstract][Full Text] [Related]
12. Selective induction of cell cycle regulatory genes cdk1 (p34cdc2), cyclins A/B, and the tumor suppressor gene Rb in transformed cells by okadaic acid.
You J; Bird RC
J Cell Physiol; 1995 Aug; 164(2):424-33. PubMed ID: 7622588
[TBL] [Abstract][Full Text] [Related]
13. Ras mutation, irrespective of cell type and p53 status, determines a cell's destiny to undergo apoptosis by okadaic acid, an inhibitor of protein phosphatase 1 and 2A.
Rajesh D; Schell K; Verma AK
Mol Pharmacol; 1999 Sep; 56(3):515-25. PubMed ID: 10462539
[TBL] [Abstract][Full Text] [Related]
14. The heat-induced hsp 70 promoter activity is negatively regulated by serine phosphatases: evidence from the effects of okadaic acid.
Chang NT; Liu AY
Biol Signals; 1992; 1(6):300-12. PubMed ID: 1339179
[TBL] [Abstract][Full Text] [Related]
15. Analysis by in vitro mutagenesis of PP2A alpha okadaic acid responsive sequences.
Kaneko S; Shima H; Amagasa T; Takagi M; Sugimura T; Nagao M
Biochem Biophys Res Commun; 1995 Sep; 214(2):518-23. PubMed ID: 7677760
[TBL] [Abstract][Full Text] [Related]
16. Cross-resistance to tumour promoters in human cancer cell lines resistant to adriamycin or cisplatin.
Nishio K; Sugimoto Y; Nakagawa K; Niimi S; Fujiwara Y; Bungo M; Kasahara K; Fujiki H; Saijo N
Br J Cancer; 1990 Sep; 62(3):415-9. PubMed ID: 2206949
[TBL] [Abstract][Full Text] [Related]
17. Mutation induction by okadaic acid, a protein phosphatase inhibitor, in CHL cells, but not in S. typhimurium.
Aonuma S; Ushijima T; Nakayasu M; Shima H; Sugimura T; Nagao M
Mutat Res; 1991; 250(1-2):375-81. PubMed ID: 1658641
[TBL] [Abstract][Full Text] [Related]
18. Differential induction of apoptosis in human breast tumor cells by okadaic acid and related inhibitors of protein phosphatases 1 and 2A.
Kiguchi K; Glesne D; Chubb CH; Fujiki H; Huberman E
Cell Growth Differ; 1994 Sep; 5(9):995-1004. PubMed ID: 7819137
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone H1 kinase expression, retinoblastoma protein phosphorylation, and cell proliferation by the phosphatase inhibitor okadaic acid.
Schönthal A; Feramisco JR
Oncogene; 1993 Feb; 8(2):433-41. PubMed ID: 8381221
[TBL] [Abstract][Full Text] [Related]
20. Protein phosphatase types 1 and/or 2A regulate nucleocytoplasmic shuttling of glucocorticoid receptors.
DeFranco DB; Qi M; Borror KC; Garabedian MJ; Brautigan DL
Mol Endocrinol; 1991 Sep; 5(9):1215-28. PubMed ID: 1663212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
